Literature DB >> 34569398

Pain in cervical dystonia: mechanisms, assessment and treatment.

Raymond L Rosales1,2, Lorraine Cuffe3, Benjamin Regnault4, Richard M Trosch5.   

Abstract

INTRODUCTION: In patients with cervical dystonia (CD), pain is a major contributor to disability and social isolation and is often the main reason patients seek treatment. Surveys evaluating patient perceptions of their CD symptoms consistently highlight pain as a troublesome and disabling feature of their condition with significant impact on daily life and work. AREAS COVERED: In this article, the authors review the epidemiology, assessment, possible mechanisms and treatment of pain in CD, including a meta-analysis of randomized controlled trial data with abobotulinumtoxinA. EXPERT OPINION: Mechanisms of pain in CD may be muscle-based and non-muscle based. Accumulating evidence suggests that non-muscle-based mechanisms (such as abnormal transmission and processing of nociceptive stimuli, dysfunction of descending pain inhibitory pathways as well as structural and network changes in the basal ganglia, cortex and other areas) may also contribute to pain in CD alongside prolonged muscle contraction. Chemodenervation with botulinum toxin is considered the first-line treatment for CD. Treatment with botulinum toxin is usually effective, but optimization of the injection parameters should include consideration of pain as a core symptom in addition to the motor problems.

Entities:  

Keywords:  AbobotulinumtoxinA; botulinum toxin; cervical dystonia; non-motor symptom; pain

Mesh:

Substances:

Year:  2021        PMID: 34569398     DOI: 10.1080/14737175.2021.1984230

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  2 in total

1.  Health-Related Quality of Life in Cervical Dystonia Using EQ-5D-5L: A Large Cross-Sectional Study in China.

Authors:  Yan Liang; Junyu Lin; Yanbing Hou; Lingyu Zhang; Ruwei Ou; Chunyu Li; Qianqian Wei; Bei Cao; Kuncheng Liu; Zheng Jiang; Tianmi Yang; Jing Yang; Meng Zhang; Simin Kang; Yi Xiao; Qirui Jiang; Jing Yang; Wei Song; Xueping Chen; Bi Zhao; Ying Wu; Huifang Shang
Journal:  Front Neurol       Date:  2022-06-23       Impact factor: 4.086

2.  OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE.

Authors:  Pinky Agarwal; Richard Barbano; Henry Moore; Marc Schwartz; Aleksej Zuzek; Marjan Sadeghi; Atul Patel
Journal:  Front Neurol       Date:  2022-06-30       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.